Prostate Cancer

E. David Crawford, MD, discusses the controversy surrounding the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, as well as the role of prostate-specific antigen testing for men with prostate cancer.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

William R. Berry, MD, medical oncologist, Duke University, talks about the differences between luteinizing hormone-releasing hormone (LHRH) antagonists and agonists.

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the existing marketing authorization for abiraterone acetate (Zytiga) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer.